These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 25359093)

  • 21. VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations.
    Na JI; Kim JH; Kim HJ; Kim HK; Moon KS; Lee JS; Lee JH; Lee KH; Park JT
    Virchows Arch; 2015 Aug; 467(2):155-68. PubMed ID: 25894433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1.
    Skorokhod A; Capper D; von Deimling A; Enk A; Helmbold P
    J Am Acad Dermatol; 2012 Sep; 67(3):488-91. PubMed ID: 22890732
    [No Abstract]   [Full Text] [Related]  

  • 23. Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma.
    Pearlstein MV; Zedek DC; Ollila DW; Treece A; Gulley ML; Groben PA; Thomas NE
    J Cutan Pathol; 2014 Sep; 41(9):724-32. PubMed ID: 24917033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAFp.V600E, p.V600K, and p.V600R Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features?
    Ponti G; Tomasi A; Maiorana A; Ruini C; Maccaferri M; Cesinaro AM; Depenni R; Manni P; Gelsomino F; Giusti F; Garagnani L; Pellacani G
    Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):30-4. PubMed ID: 26633701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of allele-specific PCR and immunohistochemistry for the detection of BRAF V600E mutations in hairy cell leukemia.
    Brown NA; Betz BL; Weigelin HC; Elenitoba-Johnson KS; Lim MS; Bailey NG
    Am J Clin Pathol; 2015 Jan; 143(1):89-99. PubMed ID: 25511147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
    Schirosi L; Strippoli S; Gaudio F; Graziano G; Popescu O; Guida M; Simone G; Mangia A
    BMC Cancer; 2016 Nov; 16(1):905. PubMed ID: 27863476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.
    Colomba E; Hélias-Rodzewicz Z; Von Deimling A; Marin C; Terrones N; Pechaud D; Surel S; Côté JF; Peschaud F; Capper D; Blons H; Zimmermann U; Clerici T; Saiag P; Emile JF
    J Mol Diagn; 2013 Jan; 15(1):94-100. PubMed ID: 23159108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays.
    Fisher KE; Cohen C; Siddiqui MT; Palma JF; Lipford EH; Longshore JW
    Hum Pathol; 2014 Nov; 45(11):2281-93. PubMed ID: 25228337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VE1 antibody immunoreactivity in normal anterior pituitary and adrenal cortex without detectable BRAF V600E mutations.
    Mordes DA; Lynch K; Campbell S; Dias-Santagata D; Nose V; Louis DN; Hoang MP
    Am J Clin Pathol; 2014 Jun; 141(6):811-5. PubMed ID: 24838325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach.
    Lasota J; Kowalik A; Wasag B; Wang ZF; Felisiak-Golabek A; Coates T; Kopczynski J; Gozdz S; Miettinen M
    Am J Surg Pathol; 2014 Sep; 38(9):1235-41. PubMed ID: 24832158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma.
    Lo MC; Paterson A; Maraka J; Clark R; Goodwill J; Nobes J; Garioch J; Moncrieff M; Rytina E; Igali L
    Br J Cancer; 2016 Jul; 115(2):223-7. PubMed ID: 27336602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VE1 antibody is not highly specific for the BRAF V600E mutation in thyroid cytology categories with the exception of malignant cases.
    Lee SR; Yim H; Han JH; Lee KB; Lee J; Soh EY; Kim DJ; Chung YS; Jeong SY; Sheen SS; Park SH; Kim JH
    Am J Clin Pathol; 2015 Mar; 143(3):437-44. PubMed ID: 25696803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma.
    Rössle M; Sigg M; Rüschoff JH; Wild PJ; Moch H; Weber A; Rechsteiner MP
    Virchows Arch; 2013 Nov; 463(5):623-31. PubMed ID: 24085553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. VE1 immunohistochemistry is an adjunct tool for detection of BRAF
    Rashid FA; Tabassum S; Khan MS; Ansari HR; Asif M; Sheikh AK; Sameer Aga S
    J Clin Lab Anal; 2021 Feb; 35(2):e23628. PubMed ID: 33305405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia.
    Andrulis M; Penzel R; Weichert W; von Deimling A; Capper D
    Am J Surg Pathol; 2012 Dec; 36(12):1796-800. PubMed ID: 22531170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay.
    Vallée A; Denis-Musquer M; Herbreteau G; Théoleyre S; Bossard C; Denis MG
    PLoS One; 2019; 14(8):e0221123. PubMed ID: 31415669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRAF V600E mutation-specific antibody: A review.
    Ritterhouse LL; Barletta JA
    Semin Diagn Pathol; 2015 Sep; 32(5):400-8. PubMed ID: 25744437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform.
    Bisschop C; Ter Elst A; Bosman LJ; Platteel I; Jalving M; van den Berg A; Diepstra A; van Hemel B; Diercks GFH; Hospers GAP; Schuuring E
    Melanoma Res; 2018 Apr; 28(2):96-104. PubMed ID: 29232304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical Study Using Monoclonal VE1 Antibody Can Substitute the Molecular Tests for Apprehension of BRAF V600E Mutation in Patients with Non-small-Cell Lung Carcinoma.
    Karbel HAE; Ejam SS; Naji AZ
    Anal Cell Pathol (Amst); 2019; 2019():2315673. PubMed ID: 31781475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intrapatient homogeneity of BRAFV600E expression in melanoma.
    Menzies AM; Lum T; Wilmott JS; Hyman J; Kefford RF; Thompson JF; O'Toole S; Long GV; Scolyer RA
    Am J Surg Pathol; 2014 Mar; 38(3):377-82. PubMed ID: 24335665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.